Review article: alternative antibacterial agents for Helicobacter pylori eradication

Area of Science:

• Microbiology
• Infectious Diseases
• Pharmacology

Background:

• Standard Helicobacter pylori eradication therapies exhibit higher failure rates in clinical practice than reported in trials.
• Antibiotic resistance is a significant and growing reason for treatment failure in H. pylori infections.
• Investigating alternative antibacterial agents is crucial for managing refractory cases.

Purpose of the Study:

• To review emerging antibacterial agents for Helicobacter pylori eradication.
• To assess the potential of novel macrolides, fluoroquinolones, furazolidone, and rifabutin.
• To identify promising options for H. pylori regimens, especially in cases of antibiotic resistance.

Main Methods:

• Literature review of current and investigational antibacterial agents for H. pylori.
• Analysis of efficacy data for macrolides, fluoroquinolones, furazolidone, and rifabutin.
• Evaluation of resistance patterns and implications for therapeutic choices.

Main Results:

• Azithromycin, spiromycin, levofloxacin, and furazolidone are promising for inclusion in H. pylori eradication regimens.
• Rifabutin demonstrates high efficacy in H. pylori infections resistant to standard therapies.
• The high cost and risk of resistance necessitate restricted use of rifabutin.

Conclusions:

• Rising antibiotic resistance necessitates exploration of alternative H. pylori eradication strategies.
• Several novel agents show potential but require further formal testing in refractory cases.
• Judicious use of agents like rifabutin is essential to preserve their efficacy and prevent cross-resistance.